Abstract:Extracellular concentrations of the predominant excitatory neurotransmitter, glutamate, and related excitatory amino acids are maintained at relatively low levels to ensure an appropriate signal-to-noise ratio and to prevent excessive activation of glutamate receptors that can result in cell death. The latter phenomenon is known as 'excitotoxicity' and has been associated with a wide range of acute and chronic neurodegenerative disorders, as well as disorders that result in the loss of non-neural cells such as oligodendroglia in multiple sclerosis. Unfortunately clinical trials with glutamate receptor antagonists that would logically seem to prevent the effects of excessive receptor activation have been associated with untoward side effects or little clinical benefit. In the mammalian CNS, the extracellular concentrations of glutamate are controlled by two types of transporters; these include a family of Na(+)-dependent transporters and a cystine-glutamate exchange process, referred to as system X(c)(-). In this review, we will focus primarily on the Na(+)-dependent transporters. A brief introduction to glutamate as a neurotransmitter will be followed by an overview of the properties of these transporters, including a summary of the presumed physiologic mechanisms that regulate these transporters. Many studies have provided compelling evidence that impairing the function of these transporters can increase the sensitivity of tissue to deleterious effects of aberrant activation of glutamate receptors. Over the last decade, it has become clear that many neurodegenerative disorders are associated with a change in localization and/or expression of some of the subtypes of these transporters. This would suggest that therapies directed toward enhancing transporter expression might be beneficial. However, there is also evidence that glutamate transporters might increase the susceptibility of tissue to the consequences of insults that result in a collapse of the electrochemical gradients required for normal function such as stroke. In spite of the potential adverse effects of upregulation of glutamate transporters, there is recent evidence that upregulation of one of the glutamate transporters, GLT-1 (also called EAAT2), with beta-lactam antibiotics attenuates the damage observed in models of both acute and chronic neurodegenerative disorders. While it seems somewhat unlikely that antibiotics specifically target GLT-1 expression, these studies identify a potential strategy to limit excitotoxicity. If successful, this type of approach could have widespread utility given the large number of neurodegenerative diseases associated with decreases in transporter expression and excitotoxicity. However, given the massive effort directed at developing glutamate receptor agents during the 1990s and the relatively modest advances to date, one wonders if we will maintain the patience needed to carefully understand the glutamatergic system so that it will be successfully targeted in the future.

Glutamate Transport and Preterm Brain Injury

Regulation of glutamate transport and neuroinflammation in a term newborn rat model of hypoxic–ischaemic brain injury

High t-PA release by neonate brain microvascular endothelial cells under glutamate exposure affects neuronal fate

The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention

Preventing Brain Injury in the Preterm Infant—Current Controversies and Potential Therapies

Enhanced autophagy contributes to excitotoxic lesions in a rat model of preterm brain injury

Glutamate-Mediated Excitotoxicity in the Pathogenesis and Treatment of Neurodevelopmental and Adult Mental Disorders

ATP-binding cassette (ABC) drug transporters in the developing blood–brain barrier: role in fetal brain protection

Glutamate controls vessel-associated migration of GABA interneurons from the pial migratory route via NMDA receptors and endothelial protease activation

Glutamate uptake is transiently compromised in the perilesional cortex following controlled cortical impact

Alpha1-antitrypsin protects the immature mouse brain following hypoxic-ischemic injury

Role of Excitatory Amino Acid Transporter 1 in Neonatal Rat Neuronal Damage Induced by Hypoxia-Ischemia

Glutamate-Mediated Blood-Brain Barrier Opening: Implications for Neuroprotection and Drug Delivery

Glutamate Transporters in Hippocampal LTD/LTP: Not Just Prevention of Excitotoxicity

Glutamate enhances survival and proliferation of neural progenitors derived from the subventricular zone

Preterm Brain Injury: Mechanisms and Challenges

Pharmacological Neuroprotection of the Preterm Brain: Current Evidence and Perspectives

Altered expression of glutamate transporters under hypoxic conditions in vitro

Transporter Reversal As a Mechanism of Glutamate Release from the Ischemic Rat Cerebral Cortex: Studies with DL-threo-beta-benzyloxyaspartate.

Glutamate transporter contribution to retinal ganglion cell vulnerability in a rat model of multiple sclerosis

Glucose and Intermediary Metabolism and Astrocyte–Neuron Interactions Following Neonatal Hypoxia–Ischemia in Rat